Briefing
Performance of Liquid Biopsy for Diagnosis and Surveillance of Human Papillomavirus-Associated Oropharyngeal Cancer
In a single-center clinical-use cohort, TTMV-HPV DNA had 91.5% sensitivity and 100% specificity for pretreatment diagnosis, and 88.4% sensitivity, 100% specificity, 100% PPV and 99.1% NPV in surveillance, with a median lead time of 47 days; about 1 in 10 negative tests among HPV-associated patients was a false negative.
- Design: Evidence level 2
- Assay: Not named in the abstract
JAMA Otolaryngol Head Neck SurgPubMed 37422913DOI 10.1001/jamaoto.2023.1937